{"filings":[{"id":555324,"accession_number":"0001104659-26-064545","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2026-05-20T20:30:26+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve increase in stock option plan shares by 900,000 at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 director nominees elected; broker non-votes of 614,643.","Ratification of Baker Tilly as auditor approved: 4,657,634 for, 4,415 against.","Amendment to 2025 Plan increases shares available to 1,017,868 from 117,868.","Shareholders representing 53.1% of outstanding common shares present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22123,"accession_number":"0001104659-26-058967","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2026-05-12T10:45:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences Q1 net loss $8.2M; PRECISE-AD interim analysis expected early Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.2M for Q1 2026, vs $7.3M in Q1 2025; cash & equivalents $63.8M as of March 31.","Closed $75.5M PIPE in Feb 2026; up to $100M additional from warrant exercises; funds operations through 2027.","PRECISE-AD Phase 1b fully enrolled (144 participants); blinded 6-month interim analysis anticipated early Q3 2026.","Unblinded 12-month top-line data expected early 2027; subcutaneous formulation development accelerated.","Lead candidate PMN310 selectively targets toxic amyloid-beta oligomers, aiming to improve safety vs plaque-directed antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103353,"accession_number":"0001104659-26-034162","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences reports FY2025 net loss of $39.7M; Phase 1b fully enrolled, $75.5M financing closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.7M in FY2025; R&D expense soared to $33.4M from $10.6M a year ago, driven by PRECISE-AD trial.","Cash of $6.1M at Dec 31, 2025; subsequent $75.5M private placement in Feb 2026 provides cash runway through 2027.","PRECISE-AD Phase 1b enrollment completed with 144 patients; six-month blinded interim data expected early Q3 2026.","PMN310 continues to show favorable safety profile with no treatment-related SAEs reported after over 12 months of dosing.","PMN310 granted FDA Fast Track Designation in July 2025; goal to advance directly into a single registrational study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103352,"accession_number":"0001104659-26-008325","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences raises up to $175M in PIPE; extends cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront gross proceeds ~$75M from ~6.8M common shares and 100K pre-funded warrants; up to ~$100M more from warrant exercise.","Pricing: common shares at $10.77 (most) and $12.13 for insiders; warrants exercisable at $14.40.","Warrants expire 60 days after PMN310 SAD topline data announcement or Feb 3, 2031.","Proceeds to fund Phase 1b Alzheimer's study and subcutaneous PMN310 development; blinded 6-month data expected mid-2026.","Co-led by Janus Henderson and Ally Bridge Group; CEO and board also participated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119601,"accession_number":"0001104659-25-121627","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ProMIS Neurosciences regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed compliance on Dec 12, 2025; matter closed.","Closing bid price >=$1.00 for 10 consecutive days Nov 28–Dec 11, 2025.","Company had received deficiency letter on Jan 8, 2025; given grace periods.","Additional 180-day grace period granted until Dec 29, 2025.","Compliance eliminates delisting risk from Bid Price Rule (5550(a)(2))."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119600,"accession_number":"0001104659-25-115182","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences Announces 1-for-25 Reverse Stock Split Effective November 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1:25 approved by board on Nov 17, 2025, effective Nov 28, 2025.","Outstanding shares will reduce from approximately 53.8 million to approximately 2.15 million.","Nasdaq deficiency notice received Jan 8, 2025 for bid price below $1.00; reverse split aims to cure compliance.","Proportional adjustments to equity incentive plans, stock options, and warrants.","No fractional shares issued; stockholders receive cash in lieu of fractional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119599,"accession_number":"0001104659-25-113978","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve reverse stock split authorization for ProMIS Neurosciences","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Nov 17, 2025; 24.3M of 53.8M shares voted (45% quorum).","Share Consolidation Proposal approved: 21,331,321 for, 2,939,187 against.","Board authorized to effect 1:5 to 1:25 reverse split within one year at its discretion.","Adjournment proposal also passed with 22.3M in favor.","No broker non-votes; action allows potential Nasdaq compliance maintenance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119598,"accession_number":"0001104659-25-109714","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences reports Q3 2025 results; Phase 1b AD trial over 85% enrolled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $15.4M at Sep 30, 2025, up from $13.3M at Dec 31, 2024; raised ~$21.6M in July 2025.","Phase 1b PRECISE-AD trial over 85% enrolled; Cohorts 1 and 2 fully enrolled.","DSMB unanimously recommended proceeding to third dose cohort; interim data Q2 2026, top-line Q4 2026.","Operating loss $11.8M for Q3 2025 vs $4.4M in Q3 2024, driven by increased R&D on PMN310 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119597,"accession_number":"0001104659-25-102137","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences appoints Slanix Paul Alex, Pharm.D., to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Alex is President and Portfolio Manager for Ally Bridge Group, a major shareholder; joined board effective Oct 22, 2025.","He receives initial option for 40,000 common shares vesting 25% immediately, rest over 36 months; annual fee $40,000.","Company highlights upcoming data readouts from PRECISE-AD trial (PMN310) in 2Q26 and 4Q26.","Board determined Dr. Alex is independent under Nasdaq listing standards.","Ally Bridge Group has made multiple investments in ProMIS, including July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136178,"accession_number":"0001104659-25-095032","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences amends CSO Neil Cashman's employment agreement with new salary, option grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual base salary increased to $500,000 CAD; discretionary bonus target of 35% of base salary.","Granted option to purchase 165,000 common shares vesting 25% on first anniversary, remainder monthly over 36 months.","Severance without cause: 9 months salary plus continued benefits; on change in control termination: same plus accelerated time-based stock vesting.","No family relationships or material transactions with officers/directors disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136177,"accession_number":"0001558370-25-011845","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences advances PMN310 to final dose cohort in Alzheimer's Phase 1b trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB unanimously recommends proceeding to third and final dose escalation cohort (20 mg/kg) after safety review.","Cohort 2 fully enrolled; no cases of amyloid-related imaging abnormalities (ARIA) observed to date.","Enrollment of Cohort 3 underway; 6-month interim data expected Q2 2026, final top-line results Q4 2026.","Trial to enroll 128 patients with comprehensive biomarker panel including pTau217, NfL, GFAP, and synaptic markers.","PMN310 holds FDA Fast Track designation; CEO to present at H.C. Wainwright conference on Sept 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136176,"accession_number":"0001558370-25-011671","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences enters up to $18M at-the-market equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement filed Aug 19, 2025; allows sale of up to $17,988,524 in common shares.","Agent H.C. Wainwright receives 3% commission on gross proceeds from any sales.","Sales commence only after SEC declares Registration Statement effective (filed Aug 13, 2025).","No minimum sales required; shares sold through Nasdaq at prevailing market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136175,"accession_number":"0001558370-25-011297","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences Q2 net loss $10.1M; PRECISE-AD enrollment >50%, no ARIA; raised $21.6M in July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.1M for Q2 2025 vs $2.6M a year ago; R&D spend $8.7M on PRECISE-AD trial.","Cash $4.5M at June 30; raised $21.6M gross proceeds in July via offerings and warrant exercises.","PRECISE-AD Phase 1b: over 50% of 128 patients enrolled; no ARIA or dropouts to date.","FDA granted Fast Track Designation for PMN310 in Alzheimer's disease in July 2025.","Company expects blinded interim results in 2Q 2026, final topline in 4Q 2026."],"consensus_eps_estimate":-4.4188,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136174,"accession_number":"0001558370-25-009636","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences raises $3M from PIPE; total proceeds of ~$12M including warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$3M gross via PIPE sale of warrants at $0.1875/share with exercise price $1.25; closing July 29, 2025.","Combined with proceeds from existing warrant exercises, total gross proceeds ~$12M.","Warrants immediately exercisable, expire in 5 years; subject to 4.99%/9.99% ownership blocker.","Proceeds to fund clinical development of lead candidate PMN310 for Alzheimer's and other neurodegenerative diseases.","Participation from existing institutional investors including Ally Bridge Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136173,"accession_number":"0001558370-25-009380","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ProMIS raises $9.2M via $0.8M registered direct and $2.4M PIPE plus $6.8M warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of pre-funded warrants for 984,736 shares at $0.8124 per share, gross ~$0.8M.","PIPE offering sold warrants for 12,616,821 shares at $0.1875 per warrant, exercise price $1.25, 5-year term, gross ~$2.4M.","Total gross proceeds of ~$9.2M including $6.8M from exercise of existing warrants; closings expected July 24, 2025.","Proceeds to advance clinical development of lead candidate PMN310 for Alzheimer's disease and for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136172,"accession_number":"0001558370-25-009352","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"FDA grants Fast Track for PMN310; ATM program terminated after minimal sales","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation to PMN310 for Alzheimer's disease.","DSMB approved dose escalation to second 10 mg/kg cohort in Phase 1b trial (May 2025).","No cases of ARIA (brain swelling/microhemorrhages) observed as of July 21, 2025.","ATM program with BTIG terminated; only $190,274 raised of $25M available (75,862 shares sold).","No termination penalties; no further shares will be sold under the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136171,"accession_number":"0001558370-25-009112","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ProMIS Neurosciences gets additional 180-day Nasdaq compliance period for bid price deficiency until Dec 29, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted a second 180-day compliance period until December 29, 2025, to regain $1.00 minimum bid price.","Company may consider a reverse stock split or other actions to cure the deficiency.","If compliance not achieved by Dec 29, 2025, Nasdaq may delist Common Shares; no assurance of success.","Common shares continue trading on Nasdaq Capital Market under ticker PMN during this period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153243,"accession_number":"0001558370-25-008600","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ProMIS Neurosciences shareholders approve 2025 stock plan and reelect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2025 Stock Option and Incentive Plan: 8,124,425 for, 828,874 against, 1,143,067 abstain.","All seven director nominees elected, including CEO Neil Warma, with no major withhold votes.","Ratification of Baker Tilly US, LLP as auditor for fiscal 2025 passed with 16,908,296 votes for.","New plan replaces 2015 Plan, authorizes 2,946,719 initial shares plus annual 5% of outstanding shares on Jan 1 each year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153242,"accession_number":"0001558370-25-007253","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Q1 net loss $7.3M; completes first cohort enrollment in PRECISE-AD trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M vs $3.6M YoY; R&D expense $5.5M on PMN310 Phase 1b trial costs.","Cash $8.4M at March 31, 2025, down from $13.3M at Dec 31, 2024.","First cohort fully enrolled and dosed in PRECISE-AD (Phase 1b) for PMN310 in Alzheimer's.","Six-month interim results expected 1H 2026; topline data by end of 2026.","PRECISE-AD designed to detect ARIA with 95% confidence; powered for biomarker changes at 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172015,"accession_number":"0001558370-25-004070","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences reports FY 2024 net income $2.8M; Phase 1b PRECISE-AD enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $13.3M at Dec 31, 2024; PIPE financing provided $30.3M upfront with potential $92.4M from warrants.","R&D expenses $10.6M (up 34% YoY) driven by Phase 1a/1b clinical costs; net income of $2.8M vs loss of $13.2M in 2023.","Gain on change in fair value of warrant liabilities of $22.6M drove net income; operating loss remains.","Phase 1b PRECISE-AD trial (NCT06750432) dosed multiple patients; plans ~100 subjects at 22 US sites.","Interim results from PRECISE-AD expected 1H 2026, topline results by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172014,"accession_number":"0001558370-25-001435","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences doses first patients in Phase 1b PRECISE-AD trial of PMN310 for Alzheimer's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patients dosed in Phase 1b PRECISE-AD trial evaluating PMN310, a humanized mAb targeting toxic Aβ oligomers.","Interim six-month results expected in 1H 2026; topline results anticipated in 2H 2026.","PMN310 selectively targets soluble amyloid-beta oligomers, avoiding monomers and plaques, potentially differentiating from current AD therapies.","Rapid enrollment underscores unmet need for better AD treatments; investigators note need for effective and well-tolerated options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172013,"accession_number":"0001558370-25-001158","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ProMIS Neurosciences separates with COO Gavin Malenfant; position eliminated.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gavin T. Malenfant separated as COO effective February 14, 2025.","Company terminated the COO role and will not replace Mr. Malenfant.","Severance benefits will be provided under a Separation Agreement referencing his employment contract."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172012,"accession_number":"0001558370-25-000427","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences releases updated corporate presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated January 27, 2025, posted to company website.","Targets neurodegenerative disease with focus on misfolded proteins.","No specific financial results, guidance, or pipeline milestones disclosed.","Filed as Regulation FD disclosure; not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172011,"accession_number":"0001558370-25-000095","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProMIS initiates Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b PRECISE-AD trial initiated; evaluating PMN310 in 100 patients with early Alzheimer's over 12 months.","PMN310 selectively targets toxic amyloid-beta oligomers, avoiding plaque to reduce ARIA risk associated with existing therapies.","Phase 1a data showed favorable safety/tolerability profile and drug concentrations in CSF supporting target engagement.","Certain interim data from PRECISE-AD expected in first half of 2026.","Trial will assess safety, tolerability, PK, biomarkers, and clinical efficacy measures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172010,"accession_number":"0001558370-25-000075","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ProMIS Neurosciences receives Nasdaq minimum bid price deficiency notice; has until July 2, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 3, 2025 for failing $1 minimum bid price rule for 30 consecutive trading days.","Has 180 calendar days (until July 2, 2025) to regain compliance by closing bid price >= $1 for 10 consecutive days.","If not compliant, may be eligible for an additional 180-day period if meets other listing standards and provides intention to cure.","Company will consider options to regain compliance but no assurance of success; shares continue trading under PMN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189004,"accession_number":"0001558370-24-015632","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Q3 net income $9.3M, cash $21.5M; Phase 1a positive; PIPE up to $122.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $9.3M for Q3 2024 vs net loss of $2.4M YoY, driven by $17.0M gain on warrant liabilities.","Cash and equivalents $21.5M at Sep 30, 2024, up from $12.6M at Dec 31, 2023.","PIPE financing closed with initial $30.3M; potential additional $92.4M from warrant exercise.","Phase 1a trial of PMN310 in Alzheimer's showed good tolerability, dose-dependent BBB crossing, supporting monthly dosing.","Phase 1b clinical trial in AD patients on track to start by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189003,"accession_number":"0001558370-24-013616","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ProMIS Neurosciences shareholders approve stock issuance for warrants at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (stock issuance for warrants) passed with 8,948,590 votes for, 121,116 against, 23,726 abstain.","Proposal 2 (adjournment) passed with 8,973,770 votes for, 116,190 against, 3,472 abstain; deemed unnecessary due to quorum.","Votes relate to warrants issued in private placement closed July 31, 2024, to comply with Nasdaq Listing Rule 5635(d).","No other matters were submitted to or voted on at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189002,"accession_number":"0001558370-24-013244","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neil Warma appointed President and CEO of ProMIS Neurosciences, effective August 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $500,000 with annual discretionary bonus target of 50% of base salary.","Granted option to purchase 1,144,122 common shares (Initial Award) and 490,338 shares (Performance Award) at $1.15 per share.","Initial Award vests 25% on grant, remainder ratably over 36 months; Performance Award vests 25% when 10-day VWAP exceeds 3x exercise price, remainder over 36 months.","Severance: 12 months' salary plus pro-rated bonus and time-based option acceleration on non-CIC termination; 18 months' salary plus benefits on change-in-control termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205482,"accession_number":"0001558370-24-011474","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences Q2 2024: Positive Phase 1a data for PMN310; secures up to $122.7M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1a of PMN310 in Alzheimer's showed no SAEs; CSF levels >100x oligomer concentration, half-life ~25 days supporting monthly dosing.","PIPE financing closed July 2024 with initial $30.3M; up to $122.7M total tied to warrant milestones from healthcare specialist investors.","Cash and equivalents $1.0M at June 30, 2024 (down from $12.6M at Dec 31, 2023); subsequent PIPE strengthens balance sheet.","Net loss $2.6M for Q2 2024 vs $2.3M in Q2 2023; R&D expenses $1.6M (up $0.6M YoY) driven by PMN310 clinical costs.","Company expects to report topline results from all five cohorts in H2 2024 and initiate a Phase 1b trial in 100 AD patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205481,"accession_number":"0001558370-24-010257","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ProMIS Neurosciences regains compliance with Nasdaq market value listing requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 22 confirming compliance with $35M minimum market value of listed securities.","Common shares traded above $35M market cap for 10 consecutive business days, July 8-19, 2024.","Matter is closed; company continues trading on Nasdaq Capital Market under ticker PMN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205480,"accession_number":"0001558370-24-010224","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences raises $30.3M in PIPE financing with warrants for up to $92.4M more","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $30.3M from sale of 9,757,669 common units at $2.15/unit and 4,371,027 pre-funded units at $2.14/unit.","Each unit includes one common share (or pre-funded warrant) and Tranche A, B, and C warrants with exercise prices of $2.02, $2.02, and $2.50, respectively.","Tranche A/B warrants subject to shareholder approval and expire upon 6-month or 12-month PMN310 data announcement; Tranche C expires July 31, 2029.","Proceeds to advance clinical development of PMN310, an antibody for Alzheimer's disease, plus working capital and general expenses.","All outstanding Series 2 Preferred Shares automatically convert into 1,166,667 common shares upon closing of this offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205479,"accession_number":"0001558370-24-010223","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProMIS reports positive Phase 1a data for PMN310 in Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PMN310 well-tolerated across four SAD cohorts (2.5-20 mg/kg); no treatment-emergent SAEs.","CSF levels dose-proportional at days 3 and 29; lowest dose >100-fold molar excess over expected oligomers.","CSF half-life ~25 days, supportive of monthly dosing.","Company plans to initiate Phase 1b in Alzheimer's patients in H2 2024.","Full dataset to be presented at a medical meeting in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205478,"accession_number":"0001558370-24-009675","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ProMIS Neurosciences receives Nasdaq notice for MVLS non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on July 2, 2024, for failing to maintain minimum Market Value of Listed Securities of $35M over 30 consecutive business days.","Has 180 days (until Dec 29, 2024) to regain compliance; MVLS must be at least $35M for ten consecutive business days.","No immediate effect on listing or trading; if not cured, common stock subject to delisting; company may appeal.","Company will monitor market value and consider available options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222408,"accession_number":"0001558370-24-009202","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ProMIS Neurosciences annual meeting approves all four proposals including director elections","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected, including Eugene Williams (4.15M for) and Neil Cashman (4.61M for); broker non-votes 3.23M.","Shareholders authorized board to set director count at 7 and adjust within articles range: 7.41M for, 70K against.","Ratification of Baker Tilly as auditor for FY2024 approved: 7.70M for, 64K against.","Approval of unallocated stock options under stock option plan passed: 3.87M for, 451K against, 3.23M broker non-votes.","Approximately 41.19% of outstanding shares present at meeting; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222407,"accession_number":"0001558370-24-008140","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences Q1 net loss $3.6M; cash $2.5M; Phase 1a data on track for mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $2.5M at March 31, 2024, down from $12.6M at Dec 31, 2023.","Net loss $3.6M in Q1 2024 versus $5.0M in Q1 2023; R&D $2.1M, G&A $1.6M.","Phase 1a PMN310 top-line data expected mid-2024; Phase 1b planned H2 2024 subject to resources.","Neil Warma appointed interim CEO in January 2024, continues as CEO and director."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222406,"accession_number":"0001558370-24-006202","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProMIS publishes study showing PMN310's superior oligomer selectivity vs other Aβ antibodies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PMN310 displayed greatest selectivity for toxic soluble Aβ oligomers among tested antibodies.","PMN310 avoided binding to plaque and vascular deposits, potentially reducing ARIA-E and ARIA-H risks.","Weekly murine PMN310 dosing at 800 mg/kg for 26 weeks in AD mice showed no detectable brain hemorrhages.","Phase 1a study in healthy volunteers ongoing; initial safety/PK data expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222405,"accession_number":"0001558370-24-004527","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Neurosciences reports FY2023 net loss $13.2M, cash $12.6M; PMN310 Phase 1a data on track for mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $12.6M at Dec 31, 2023, up from $5.9M; Q3 2023 PIPE raised $20.4M gross.","Net loss $13.2M for FY2023 vs $18.1M in FY2022; R&D expenses $7.9M vs $16.1M.","Phase 1a trial of PMN310 for Alzheimer's dosed Nov 2023; top-line safety/PK data expected mid-2024.","Lead vaccine candidate PMN400 selected for synucleinopathies (MSA, Parkinson's) in Jan 2024.","Neil Warma appointed interim CEO in Jan 2024; US/international patent allowances for AD antibody in Mar 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241928,"accession_number":"0001558370-24-000118","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Promis Neurosciences enters $25M ATM offering agreement with BTIG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At-the-market offering up to $25M of common shares via BTIG as sales agent.","Commission of 3% of gross proceeds; shares sold on Nasdaq based on Company instructions.","No minimum sales requirement; Company controls timing and price of sales.","Offering effective Jan 5, 2024; shares issued under effective S-3 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241927,"accession_number":"0001558370-24-000021","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences appoints Neil Warma as interim CEO after Gail Farfel departure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Gail Farfel separated as President/CEO and Board member effective Dec 30, 2023; will receive severance per agreement.","Neil Warma appointed interim CEO effective Dec 30, 2023; continues as Board member.","Compensation: $250k base salary, up to $400k milestone bonus, and options for 200k shares.","Warma brings neuroscience background; company plans to advance PMN310 in Alzheimer's and seek partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259359,"accession_number":"0001558370-23-019700","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"ProMIS Neurosciences exchanges Series 1 Preferred for Series 2 at 60:1; no Series 1 outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["70,000,000 Series 1 Preferred exchanged for 1,166,667 Series 2 Preferred (60:1 ratio).","Series 2 Preferred automatically converts into Common upon $14M+ equity financing (Mandatory Conversion Event).","Prior nine-month financing limitation terminates as of December 4, 2023.","Amended articles to create Series 2; rights substantially similar to Series 1 except conversion trigger.","Holders include Crocker Mountain, Kraft entities, McCance Trust, and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259358,"accession_number":"0001104659-23-119726","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Promis Neurosciences doses first subject in Phase 1a trial of PMN310 for Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human Phase 1a study of PMN310, a monoclonal antibody selective for toxic Aβ oligomers, is underway.","Up to 5 cohorts of 8 healthy volunteers each receive a single ascending dose; 85-day study with optional Day 120 follow-up.","Initial safety and pharmacokinetic data expected in first half of 2024.","Company raised >$20M in Q3 2023 private placement to support development through clinical milestones.","CEO Gail Farfel highlights transition to clinical stage and potential differentiation from other AD treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259357,"accession_number":"0001558370-23-019067","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Q3 net loss $2.4M, cash $16.9M; starts Phase 1a PMN310 Alzheimer's trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.4M in Q3 2023 vs $6.0M in Q3 2022; R&D expenses dropped to $1.1M from $4.6M.","Cash $16.9M at Sep 30, 2023, up from $5.9M at Dec 31, 2022, after $20.4M gross PIPE proceeds.","Phase 1a trial of PMN310 for Alzheimer's: first subjects dosing expected Nov 2023; early cohort results in H1 2024.","Raised $20.4M via private placement of ~10M shares and ~955K pre-funded warrants in August 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276631,"accession_number":"0001104659-23-094126","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences raises $20.4M in PIPE financing to fund clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$20.4M from sale of common share units at $1.88/unit and pre-funded units at $1.87/unit.","Participation from Affinity Asset Advisors, Ally Bridge Group, Sphera Healthcare and other accredited investors.","Proceeds to advance clinical development of PMN310, lead therapeutic candidate, and for working capital.","Insiders (directors and officers) subscribing for ~$145,000 of units under related party transaction exemptions.","Financing expected to close on August 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276630,"accession_number":"0001558370-23-014916","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS Q2 net loss $2.3M; cash drops to $1.2M; PMN310 IND cleared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.3M vs $2.7M YoY; R&D expense fell to $1.0M from $3.2M.","Cash and equivalents $1.2M at June 30, 2023, down from $5.9M at Dec 31, 2022.","PMN310 received FDA IND clearance in May 2023; Phase 1a planned subject to capital.","Preclinical data at AAIC 2023 showed PMN310 selectively targets toxic amyloid beta oligomers with potential for improved safety.","Shares delisted from TSX in July 2023; now trades solely on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276629,"accession_number":"0001558370-23-011879","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"ProMIS Neurosciences continues from CBCA into Ontario under OBCA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Continuance effective July 13, 2023; approved by shareholders on June 29, 2023.","Company now governed by Ontario Business Corporations Act; CBCA no longer applies.","No change in business, headquarters, management, assets, or Nasdaq/TSX listing.","OBCA has no director residency requirement; short selling by insiders not prohibited.","Shareholder rights generally comparable; some differences in dissent and oppression remedies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276628,"accession_number":"0001558370-23-011766","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences to voluntarily delist from TSX, consolidate trading to Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary delisting from TSX effective as of close of trading on July 21, 2023.","Common shares will continue to trade on Nasdaq under symbol PMN without interruption.","Company cites cost savings and management time savings from eliminating dual listing.","Shareholder approval not required; Nasdaq is deemed an acceptable alternative market by TSX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294393,"accession_number":"0001558370-23-011636","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ProMIS Neurosciences shareholders elect all eight directors, ratify auditor, approve continuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected: highest 3.47M for Cashman; lowest 3.05M for Wyman; broker non-votes 914k.","Ratification of Baker Tilly US, LLP as auditor for FY2023: 4.29M votes for, 99.6k against, 1.1k abstain.","Continuance to Ontario approved: 4.54M for, 103.9k against, 6.7k abstain; overall quorum 93.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294392,"accession_number":"0001558370-23-009944","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProMIS reports Q1 2023 results, FDA clears IND for Alzheimer's candidate PMN310","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA cleared IND for lead therapeutic candidate PMN310 for Alzheimer's disease; phase 1 enabling activities underway.","Cash and cash equivalents of $3.3M as of March 31, 2023, down from $5.9M at December 31, 2022.","Net loss of $5.0M for Q1 2023 compared to $2.1M in Q1 2022, driven by increased R&D spending on PMN310.","R&D expenses rose to $3.5M from $1.9M YoY, primarily for drug product manufacturing and IND filing costs.","Preclinical data presented at AD/PD and AAN conferences showing PMN310 selectivity and memory protection in AD models."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294391,"accession_number":"0001104659-23-056920","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences receives FDA IND clearance for Alzheimer's antibody PMN310","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.","Preclinical data showed PMN310's selective binding to toxic oligomers with minimal plaque binding, potentially reducing ARIA risk.","Company plans to initiate Phase 1a trial to evaluate pharmacokinetics, safety, and tolerability in healthy volunteers.","CEO Gail Farfel called the clearance an important corporate milestone toward a next-generation AD therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294390,"accession_number":"0001104659-23-043318","cik":1374339,"company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProMIS Neurosciences submits IND to FDA for Alzheimer's antibody PMN310","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND filed for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.","PMN310 designed for high selectivity to toxic oligomers, potentially reducing ARIA risk vs other antibodies.","Company expects to become a clinical-stage company pending FDA clearance of the IND.","Preclinical data showed strong ex vivo target engagement and favorable in vitro comparison to other Aβ antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23138268.186157517,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-10T23:59:59+00:00|294390"}